Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20241879 | 0.84 | TRPV4 (0.40) | KMT2AARTRPV4S1PR1SRC | |
| SCHEMBL13868310 | 0.82 | CD44 (0.41) | CD44POLBKMT2AALDH1A1TSHR | |
| SCHEMBL28408336 | 0.77 | TRPV4 (0.43) | CD44POLBKMT2AALDH1A1TSHR | |
| SCHEMBL25235179 | 0.77 | TRPV4 (0.43) | KMT2AALDH1A1ARTRPV4PGK1 | |
| SCHEMBL19931598 | 0.77 | CD44 (0.41) | CD44POLBKMT2AALDH1A1TSHR | |
| SCHEMBL17629777 | 0.77 | KHK (0.43) | ALDH1A1ARTRPV4 | |
| SCHEMBL23754017 | 0.77 | TRPV4 (0.39) | ALDH1A1TSHRARTRPV4SLC22A12 | |
| SCHEMBL20045535 | 0.77 | ALDH1A1 (0.36) | ALDH1A1TSHRARTRPV4SLC22A12 | |
| SCHEMBL404910 | 0.77 | CD44 (0.58) | CD44POLBKMT2AALDH1A1TSHR | |
| SCHEMBL15407630 | 0.77 | GAA (0.44) | KMT2AALDH1A1TSHRTRPV4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | CD44 3656/4885POLB 3068/4885KMT2A 4451/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | CD44 3656/4885POLB 3068/4885KMT2A 4451/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | CD44 3656/4885POLB 3068/4885KMT2A 4451/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | CD44 2435/4885POLB 2983/4885KMT2A 4351/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | CD44 4306/4885POLB 2579/4885KMT2A 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.